DETECTION OF AUTOLOGOUS BLOOD DOPING

- 2 Christer Malm, ^{1,2} Irene Granlund, ² Michael Hall, ² Pernilla Lindén, ² Magnus Ericsson, ^{3,4} James I.
- 3 Langridge,⁵ Lee A. Gethings,⁵ Chris Hughes,⁵ and Nelson Khoo²
- ¹Section of Sports Medicine, Department of Community Medicine and Rehabilitation, Umeå
- 5 University, Umeå, Sweden. ²Pro Test Diagnostics AB, Umeå, Sweden. ⁴AFLD Agence Française de
- 6 Lutte contre le Dopage, Département des analyses, Châtenay-Malabry, France. ⁵Department of
- 7 Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden. ⁵Waters Corporation, Stamford
- 8 Avenue, Altrincham Road, Wilmslow, UK.

9 ABSTRACT

1

- 10 **Objectives:** Autologous blood transfusion (ABT) enhances athlete's performance, is banned as doping
- by the World Anti-Doping Agency (WADA). Currently, there is no implemented detection method for
- 12 ABT. Transfusion of one's own, long-term cryopreserved red blood cells (cryo-RBC) immediately
- 13 increases circulating RBC count, hemoglobin mass, blood volume and oxygen carrying capacity,
- 14 resulting in enhanced physical performance. Functional viablity of cryo-RBC are maintained for
- decades, but storage lesions lead to removal of damaged RBC from circulation days after transfusion,
- with remaining circulating cryo-RBC displaying normal half-life. Methods: The cytosolic RBC
- 17 peptidome from 22 human subjects (12 men and 10 women) was analyzed by UHPLC-MS/MS before
- 18 and after ABT with cryo-RBC. As a control group and for investigation of confounders, 14 elite
- athletes and 5 recreational subjects were sampled multiple times, also at high altitude. **Results:** Here
- 20 we report alteration in the cytosolic peptidome of circulating RBC weeks after ABT, discriminating
- doped from non-doped human subjects. A valid discriminating multivariate model (OPLS-DA) based
- on <200 peptides was accomplished ($R^2/Q^2 = 0.88/0.59$, P CV-ANOVA < 0.0001, ROC AUC = 0.97).
- 23 Models did not show bias for sex, high altitude or elite endurance training and racing. Conclusion:
- 24 Identified peptides with low intra- and inter-individual variation, and high multivariate model weight
- and probability scores, create a direct method for the detection of autologous blood doping.
- 26 Key words: endurance, performance, doping, proteomics
- 27 Correspondence to: Christer Malm christer.malm@umu.se
- 28 Word count: 3286

Introduction

29

- Autologous blood transfusion (ABT) enhances the athlete's performance, and is viewed as doping. 30 31 thus banned by the World Anti-Doping Agency (WADA); but with no implemented direct detection 32 method, it remains difficult to survey by sporting authorities. Because cold-stored (+1° to +4°C) blood is viable for a maximum of 42 days,³ during which time the athlete's physical performance is 33 compromised from blood donation, 4,5 and erythropoietin is readily detected; 6 the blood doping method 34 of choice for cheating athletes is transfusion of one's own, long-term cryopreserved red blood cells 35 36 (cryo-RBC). Upon transfusion, increases are immediately observed in circulating RBC count, hemoglobin mass, blood volume and oxygen carrying capacity, resulting in enhanced physical 37 performance.^{1, 9, 10} Cryo-RBC in storage maintain their function for more than a decade.^{11, 12} but 38 display storage lesions altering physical properties^{13, 14} of both cytosolic¹⁵ and membrane ¹⁶ proteins, 39 leading to an expedited removal of damaged cryo-RBC from circulation 6 h to 48 h after transfusion. 17, 40 ¹⁸ The remaining circulating cryo-RBC display normal half-life¹⁹ despite observable altered metabolic 41 profiles²⁰ and irreversible cytosolic protein alterations, derived from the process of freezing and 42 thawing.21 43 44 Today, indirect detection of ABT exist using the hematological module of the Athletes Biological Passport (ABP). The ABP uses longitudinal monitoring of standard hematological parameters to 45 identify possible blood manipulations,²² and can be considered less effective than anticipated in 46 detecting ABT.^{23, 24} Also, the ABP is affected by exercise²⁵ as well as increased fluid intake.²⁶ 47 Moreover, several tests claim to detect ABT via: immunological reactions, ²⁷ hematological variables. ²⁸ 48 phthalate/metabolites²⁹ and CO rebreathing^{30, 31}, but no test is implemented for doping detection. 49 A direct and valid detection method for ABT remains elusive and unavailable, 1, 32, 33 but must include 50 intracellular biomarkers, as all cell-surface alterations, including storage-induced, 34 initiate rapid 51
- removal of cryo-RBC from circulation by spleen macrophages, 18 thus circumventing the effectiveness 52
- 53 of such markers for detection of ABT.
- 54 Proteomic and bioinformatic methodologies allows detection of sample differences in minutiae across
- 55 subjects and chronology. We proposed that screening the cytosolic fraction of circulating RBC
- 56 (RBCc) sampled before and after cryo-RBC transfusion, will provide markers specific to ABT.
- 57 Subsequently, applying liquid chromatography tandem mass spectrometry (LC-MS/MS) analysis will
- 58 generate biomarkers (proteins and/or peptides), differentiating the two states of pre- and post-
- 59 transfusion, defining Clean and Doped samples, respectively. In addition, identified biomarkers will be
- 60 curated to remove those markers biased for sex, exercise, hypoxia and high-altitude exposure.

METHOD (APPENDIX 10) 61

SUBJECTS 62

- Autologous blood transfusion of eight men (age 29; 24-36 years [mean; min-max]) and seven women
- 64 (age 27; 23-38 years) with peak oxygen consumption (VO_{2peak}); Men (4.3; 3.2-5.0 L·min- $^{1}/53$; 33-59
- 65 mL·min-¹·kg-¹) and women (3.0; 2.4-3.6 L·min-¹/48; 45-56 mL·min-¹·kg-¹) with five recreational
- 66 Control subjects sampled in parallel (Appendix 2, 3 & 9). Fourteen international level elite endurance
- athletes investigated confounders by resting blood samples at: Sea Level (<80 m), High Altitude
- Training (>1500 m), Hypoxic Tents (>10 h/day, 14 days, 3-4000 m) and in the Hypoxia group up to
- 69 28 days after a multisport race (700 km in 4.5 days reaching altitudes up to 4500 m, Appendix 2, 3 &
- 70 9).
- 71 TRANSFUSION
- Women donated one (450 mL) and men two (900 mL) units of whole blood as s described in detail
- previously ^{1, 18}. Whole blood was collected and glycerolized RBC stored at -80°C until transfusion.
- 74 SAMPLING
- 75 In total, participants (21 men and 15 women, Appendix 2, 3 & 9) gave 307 venous blood samples,
- where 85 were in a Doped state after cryo-RBC transfusion, 173 in a Clean state and 49 samples taken
- directly from the Blood Donation Bag (timeline for Transfusion indicated in Figure 1). Some samples
- were used multiple times (noted as Batch I, II and III in Tables and Appendices), resulting in 392 LC-
- 79 MS/MS sample injections (Appendix 2, 3 & 9).
- 80 PREPARATION
- 81 Erythrocytes were lysed, the cytosol isolated and hemoglobin removed before determination of protein
- 82 concentration. Pre-digest internal peptide standard was added before trypsin digestion. Clean-up of
- trypsin digest samples was performed by C18 and dried samples were stored at -80°C.
- 84 NANO-UPLC-MS/MS ANALYSIS
- 85 Internal retention time standards, pre-LC internal standard and TFA were added before injection using
- a nanoACQUITY UltraPerformance UPLCTM (Waters). Separated peptides were analyzed using a
- 87 Synapt G2TM or G2SiTM (Waters). Initial data evaluation used the MassLynxTM software (Waters).
- 88 DATA PROCESSING AND ANALYSIS
- 89 Raw data processing, alignment, peptide identification, quantification (relative abundance) and
- 90 comparative analysis were performed using Progenesis QI for Proteomics (Waters), Protein Lynx
- Global Server (Waters) and the open-source Skyline (https://skyline.ms). For peptide identification a
- 92 curated human proteome database (Swiss-Prot) was used, acquired from Uniprot (www.uniprot.org).
- 93 STATISTICS
- 94 Mixed Model using Restricted Maximum Likelihood (REML) and multivariate analysis (MVA), with
- 95 Principal Component Analysis (PCA), Orthogonal Projections of Latent Structures (OPLS)³⁵, and its

- 96 discriminant analysis OPLS-DA³⁶ were applied. Samples from blood donation (Clean) and after
- 97 transfusion (Doped), High Altitude Training, Hypoxic Tents and Elite Endurance Athletes created
- MVA models (Appendix 5 & 9). Regression (R^2) and prediction (Q^2) were investigated, with valid R^2
- and Q^2 set to > 0.60, 35,37,38 in three datasets: Training (Men), Testing (Women) and Validation (Men
- and Women) for Screening, Selection and Validation of Biomarkers (Appendix 5 & 9).
- 101 CONFOUNDERS
- Data from two LC-MS/MS analyses which differed to the biomarker screening dataset (Appendix 6),
- were used to create four OPLS-DA models investigating confounders. Appendix 7: 1) If peptides
- separating fresh and cryo-stored RBCc could separate Clean from Doped subject 2) Bias for Elite
- Endurance training and 3) Summary model (four Y -variables) of Clean, Doped, Elite Athletes and
- High-Altitude Training. Appendix 8: Bias for High Altitude Training and Hypoxic Tents.
- 107 PATIENT AND PUBLIC INVOLVEMENT STATEMENT
- 108 Participants in the study were recruited locally. Each participant was given continuous feedback.
- Lectures informed staff, participants and colleagues of the study objectives.
- 110 ETHICAL CONSIDERATIONS
- The Ethics Board for Northern Sweden approved the study (DNr: Ö1-2009, 08-196M, 2011-408-
- 32M), and transfusions performed in a hospital clinical. Risks reviewed in Appendix 1. The study was
- conducted in accordance with the WMA Declaration of Helsinki 2013. Data is encrypted and stored on
- security protected servers.
- 115 RESULTS (EXTENSIVE MODELS IN APPENDIX 5 & 9).
- Normal distribution of samples is visualized in a PCA model for Hematological (Figure 1A) and
- 117 Proteomic (Figure 1B) data.
- 118 HEMATOLOGY
- Autologous blood transfusion changed hematological variables (Figure 1, Table 3, Appendix 3 and 4),
- 120 but with large individual variations, making regression analysis and prediction of samples to Clean
- 121 (Before blood donation) or Doped (after transfusion of cryo-RBC) unreliable (Figure 2 and 3,
- 122 Appendix 3 and 4). The visualized OPLS-DA analysis (Figure 3) indicate models with low R² (<0.6)
- and Q^2 (<0.2) in the Summary of Fit plot, and sensitivity and specificity displayed in the ROC curve,
- where AUC for Men = 0.97 and Women = 0.79. Selection for prediction by VIP Pred indicate
- different variables of importance for men and women.
- 126 Interpretation: Hematological data can generate weak regression models with low predictive power,
- even when used in combinations.

128 FIGURE 1 HERE - Hematology 129 130 FIGURE 2 HERE – PCA models 131 **PROTEOMICS** 132 Multivariate data analysis (MVA) of quantified and identified peptides from circulating RBC cytosol 133 created significant and cross-validated PCA and OPLS-DA models for regression and prediction of 134 analyzed samples to Clean and Doped groups (Figures 3, Appendix 6). Separation of Clean and Doped 135 samples by OPLS-DA analysis resulted in R² and Q²>0.9 for men, and R²>0.6 and Q²<0.2 for women, displayed in the Summary of Fit plot. Sensitivity and specificity are displayed in the ROC curve, 136 137 where AUC for Men = 1.00 and Women = 0.68. Selection for prediction by VIP Pred indicate 138 different variables of importance for men and women. 139 Further results when screening for biomarkers are displayed in Figure 4, where data is divided into 140 three sets; Training (Men), Testing (Women) and Validation (Men and Women). Because the RBC 141 cytosolic fraction (Hb removed) of RBC (RBCc) had different peptidomic profile in men and women, R^2 (cum) = 0.99/ Q^2 = 0.92; P < 0.0001, different biomarkers in each sex may be assumed. Models 142 143 excluding sex-separating peptides were also investigated (Appendix 6). 144 Training (Men) the model pared down data to the 200 most important peptides, separating Clean from Doped both in PCA and OPLS-DA analysis, with high R^2/Q^2 of 0.90/0.79, cross-validated by 145 100 permutations and predicting 28/28 samples to the correct class. AUC = 0.96. 146 147 **Testing (Women)** of the model as accomplished by applying the 200 peptides from the Training model on a cohort of women, resulted in R^2/Q^2 of 1.00/0.52, cross-validated by 100 permutations and 148 149 predicting 28/28 samples to the correct class. AUC = 0.92. 150 Validation (Men and Women) of selected peptides for prediction of Doping used both male and 151 female subjects in combination, starting with the 200 peptides from men and removing peptides until an optimized model was achieved, containing 50 peptides, reaching, R²/Q² of 0.88/0.59, cross-152 validated by 100 permutations and predicting 56/56 samples to the correct class. AUC = 0.97. 153 154 Ranking peptides by OPLS-DA loading scores suggests potential candidates for development of 155 diagnostic tools applicable for the detection of autologous blood doping in humans (Figure 5). 156 Merging hematological and peptidomic signature variables, demonstrate a lower loading impact of 157 hematological variables, compared to peptides (Figure 5) in MVA modeling, supporting the previously demonstrated¹ lack of predictive power using hematology (Figure 1, 2 and 3). 158 159 FIGURE 3 HERE - OPLS-DA models

160 FIGURE 4 HERE – Training/Testing/Validation 161 162 163 FIGURE 5 HERE – Loading plot 164 **CONFOUNDERS** 165 In vitro peptides quantified and identified from analysis of the cytosolic fraction of RBCs, harvested 166 from transfusion bags before and after cryo-preservation, created significant and cross-validated 167 OPLS-DA models for the two conditions (Bags, Figure 6). In vitro identified peptides did not create 168 significant and cross-validated OPLS-DA models for venous blood samples taken before and after 169 cryo-RBC transfusion (i.e. autologous blood doping, Blood Sample, Figure 6). In vivo peptides 170 quantified and identified from analysis of RBCc taken by venous blood sampling in humans before 171 and after cryo-RBC transfusion, created significant and cross-validated OPLS-DA models (Appendix 172 9/Table 6/Model 19). In vivo Doped peptides (top 200 from the OPLS-DA coefficients for Doped) also 173 separated venous blood samples taken from individuals (Elite Athletes) trained at High Altitude, living 174 in Hypoxic Tents and Elite Athlete sampled at sea level (Figure 6, Appendix 9/Table 6). In the 175 Summary plot (Figure 6), samples from Doped do not overlap with other investigated cohorts. 176 FIGURE 6 HERE - Confounders 177 **Interpretation:** Proteomic data can generate strong regression models with high predictive power, 178 both for Men and Women, with no impact (bias) from investigated confounders. 179 **DISCUSSION** 180 Autologous blood doping with cryo-RBC is detected in human subjects by unlabeled, quantitative 181 nano-UPLC-MS/MS. Comparing peptide patterns from RBCc separated Clean from Doped individuals using the multivariate discriminating method OPLS-DA (R²>0.90, O²>0.90, p<0.001, 182 183 X<200). Cross-validated models did not show bias for sex, strenuous physical exercise, hypoxia 184 exposure and high-altitude training in elite athletes. In comparison, hematological variables alone 185 failed to generate significant OPLS-DA models when analyzed in parallel blood samples. 186 Investigations were executed using prospective case-control, cohort and cross-sectional study designs. 187 BIOMARKERS IN BIOLOGICAL MATRIXES Biomarkers for any diagnostics must be reliable, sensitive, specific, and discriminative. 39, 40 In 188 189 addition, validation must determine predictability of unknown samples to correct state (i.e. Clean or 190 Doped). For practical implementation in anti-doping efforts to keep sports clean, aspects such as

192

193

194

195

196

197

198 199

200

201

202

203

204

205

206

207

208

209

210211

212

213

214

215

216

217

218

219

220

221

222

223224

225

available sample matrices, Doping Control Laboratory (DCL) facilities, transport systems and cost are also important considerations. Red blood cells are closed systems, unable to synthesis protein and with a life cycle of approximately 120 days in adult humans. 41 Once set in circulation, RBC undergo an ageing processes, with changing plasma membrane and external structures,^{3,41} making them susceptible to recognition and subsequent systemic removal by spleen macropalges. 18, 42 While homologous blood transfusion can be detected via surface antigens,³ the only current method to detect autologous blood transfusion is via Hb mass by CO-rebreathing. 43, 44 The WADA research initiative states that there is no unequivocal detection method for autologous blood doping, as CO is toxic it has no relevance in anti-doping control of healthy athletes who would be reluctant to have a toxic agent imposed on them repeatedly. Autologous blood doping with cryo-RBC is the preferred choice of cheating athletes, as RBC in cold storage (+4°C) has a known clinical safety limit of 42 days after donation, necessitating repeated blood donation, and subsequent decreased performance, ⁴⁵ during the preparation phase for competition as the red blood cell population are regenerated to compensate for the loss. Cryo-RBC on the other hand, may be stored for decades.¹² Regardless of storage procedure, a fraction of all transfused RBCs is damaged and, just as aging RBC, removed from circulation not in 120 days but within 6 h to 48 h. 19 Consequently, RBC with intact cell surface proteins, and remaining in circulation 48 h after transfusion, may be viewed as circulating time-stamps, containing bioinformation useful in the detection of ABT. 46, 47 The cryo-induced formation of ice crystals, permanently damaging cytosolic RBC proteins,²¹ serves as a probable, but not the only inducer of potential biomarkers - creating unique detectable peptide fragments after protein trypsinization. An additional advantage of using altered cytosolic biomarkers, compared to hematological variables, is that plasma volume changes will not influence analytical results. The present series of studies follows a general procedure for biomarker discovery and validation, ^{39, 40} including establishing robust baseline values by repeated sample collection at rest in all investigated groups, transports and storage conditions and routine procedures in accredited, clinical laboratories. Current approaches with multiplexing orthogonal biomarkers into one assay increase robustness to confounders and inter-laboratory variations, while reducing analytical costs. The results are reliable, validated for several known possible confounders, have high specificity, sensitivity and discriminating power.39 TRUE POSITIVES AND NEGATIVES One unavoidable challenge when investigating ABT is the inclusion of true positives, vital for all statistical analysis and legal actions. As previously directly shown by us¹, argued by others²³ and here again demonstrated (Figures 2 and 3) - hematological markers are indirect indicators of ABT, and will always be subject for interpretation (what are limits for normal intra-individual variation?) and

227

228

229

230231

232

233234

235

236

237

238

239

240

241

242

243244

245246

247

248

249

250

251

252

253

254

255

256

257

258

259260

significant confounder (exercise, hydration, high altitude, diet, illness etc.) opening for cheating athletes to be legally dismissed from conviction. When investigating hematological intra- and interindividual variations over time in Clean vs. Doped subjects, neither regression nor prediction models are reliable (Appendix 5). In the context of doping detection, median/range values from elite athletes²², ^{31, 48} (unknown status of doping) are not relevant for individual judgements, as mean/median values from true positively doped subjects¹ can also stay within 95% CI (Figure 2 & Appendix 5). Also, when using cold stored RBC, detection of ABT by hematological measurements has shown low specificity and sensitivity^{31, 49, 50}. Hematological variables changed with investigated confounders, even when more advanced statistical approaches are applied (Figure 1). The present use of clean elite athletes for comparison is not often possible when validating biomarkers for doping, as athletes cannot serve as subjects. Using cohorts of elite athletes from routine sampling as controls adds uncertainty to any model, as their true state of Clean or Doped cannot be known. Elite athletes participating in this study volunteered to live for extended periods of time in hypoxic tents, before training and competing at high altitude. Knowing they would be tested for blood doping, it is highly unlikely doped athletes are included, also confirmed by the OPLS-DA analysis. WINDOW OF DETECTION Theoretically, transfusion of cryo-RBC can be detected for up to 120 days, if the youngest RBCs at time of donation could be identified after transfusion.¹⁹ Limits of Quantification (LOQ) with the presented method is still not fully investigated, but a few samples (N=14) taken four and five weeks after transfusion (Batch I) are below critical limits (99%) when analyzed by Hotelling's T² indicating that these samples are no different compared to samples taken one to three weeks after transfusion. Because cryo-induced peptide abundance diminish as RCBs are aged and removed, LOQ should be determined by target analysis methods. Determining LOQ will also be valuable for detection of microdosing with cryo-RBC, a practice likely to be used by cheating athletes to avoid detection. ALTERNATIVE INTERPRETATIONS AND LIMITATIONS An alternative biomarker selection procedure for Clean vs. Doped models could be to exclude the most important (highest OPLS-DA coefficient scores) peptides separating RBCc from Men and Women taken at rest (Clean). This approach may potentially remove peptides important for detecting reinfusion of only one unit cryo-RBC. Creating OPLS-DA models that include 5000 peptides which are most relevant for separating of Men and Women, then selecting the 200 peptides with the highest coefficient score for Doped, creates models for Clean vs. Doped, still biased for sex in the regression models, but without predictive power: Men vs. Women $R^2 = 0.45$ and $Q^2 = -1.55$, CV-ANOVA p =1.00. Data remaining after removing 5 000 peptides from the model of Men vs. Women, provides an OPLS-DA model for Clean vs. Doped using 200 peptides with $R^2/Q^2 = 0.64/0.24$, CV-ANOVA p <

0.001. Removing 10 000 peptides gives $R^2/Q^2 = 0.79/0.38$, CV-ANOVA p < 0.001. As discussed,

- 261 approaching the biomarker selection via a Training set consisting of Men (reinfused with two units
- 262 RBC) resulted in stronger regression and prediction models (Figure 4). Alternatively, the models for
- 263 sex investigate cryo-RBC reinfusion of one vs. two units. Data from the present study design cannot
- distinguish these two options.
- Regardless, with the presented list of peptides (Appendix 6 & 9) ABT can be detected in both men and
- women, reinfused with either one or two units cryo-RBC for at least two weeks after reinfusion.

CONCLUSION

267

- Doping with ABT is directly detected by cryo-induced alterations in cytosolic RBC peptides,
- with high sensitivity and specificity in both men and women.
- Elite endurance training at low and high altitude did not significantly affect peptides
- discriminating Clean from Doped samples.
- Presented peptides can be used for direct detection of autologous blood doping using standard
- 273 equipment available in Doping Control Laboratories.

274 FUTURE RESEARCH

- 275 The potential of selected peptides for labeling and direct detection of autologous blood doping by
- target analysis should be explored, with independent prospective case-control trials and cross-sectional
- studies, including inter- and intra-laboratory analytical variability. Larger, both-sex cohorts of clean
- and doped subjects, elite athletes and different ethnic groups need to be sampled for investigation of
- sensitivity, specificity, false positive and likelihood ratios.

280 ACKNOWLEDGEMENTS

- Outstanding entributions were given by: The staff at Sunderby Hospital, Luleå for hosting the first
- 282 series of blood transfusions, under the medical responsibility of Staffan Wikström. The staff at
- Winternet, Boden for performing all exercise testing and blood sample collection, especially Anna
- 284 Tano-Nordin and Eva Edholm. The staff at Björknäs Health Center, Boden under guidance of Lillian
- Falk for organizing the first round of blood donations. The staff at Huddinge Blood Central, where
- 286 Eva Trollin and Linda Larsson were responsible for blood cryopreservation, and head of unit Hans
- 287 Gulliksson kindly supported the project. Blood donation, cryopreservation and transfusion, as well as
- 288 blood sampling, has also been executed by the Center for Stem Cell Apheresis and Management at
- 289 Huddinge University Hospital, where Emma Watz, Beatrice Asperval Diedrich and Peter Matha
- 290 managed the study. Ogonna Obudulu for consultation on multivariate statistics. Gunnar Wingsle for
- 291 technical support with LC-MS/MS, Raik Wagner and Johan Jakobsson for proof-reading and
- 292 improving the manuscript. All participating subjects for enduring blood loss, exhaustive exercise and
- 293 numerous trips to the labs.

- CONTRIBUTORS
- 295 CM conceived the idea, received funding, developed the methodology and clinical study, performed
- statistical analysis and was lead writer. IG, MH, PL developed the methodology, prepared samples,
- 297 executed LC-MS/MS analysis and data cleanup. JL, LG, CH developed the method and executed LC-
- 298 MS/MS analysis. NK developed the methodology, designed experiments and improved data cleanup.
- 299 All author participated in writing and editing the final manuscript.
- 300 Funding

- 301 This work was funded by WADA: R07A1CM, 08C06CM and T13M04CM, VINNOVA; 2009-00462,
- 302 2013-05410, 2015-05299, 2018-0188, Centrum för Idrottsforskning; 2008 88/08 and Umeå Biotech
- 303 Incubator. The funders had no role in study design, data collection and analysis, decision to publish, or
- 304 preparation of the manuscript.
- 305 REFERENCES
- 306 1. Malm CB, Khoo NS, Granlund I, et al. Autologous Doping with Cryopreserved Red Blood Cells -
- 307 Effects on Physical Performance and Detection by Multivariate Statistics. PLoS One
- 308 2016;11(6):e0156157. doi: 10.1371/journal.pone.0156157
- 309 2. WADA. Blood doping. https://www.wada-ama.org/en/questions-answers/blood-doping#item-596,
- 310 2019.
- 3. Almizraq R, Tchir JD, Holovati JL, et al. Storage of red blood cells affects membrane composition,
- 312 microvesiculation, and in vitro quality. Transfusion (Paris) 2013;53(10):2258-67. doi:
- 313 10.1111/trf.12080 [published Online First: 2013/01/17]
- 4. Berglund B, Birgegard G, Wide L, et al. Effects of blood transfusions on some hematological
- variables in endurance athletes. *Med Sci Sports Exerc* 1989;21(6):637-42. [published Online First:
- 316 1989/12/01]
- 5. Ekblom B, Goldbarg AN, Gullbring B. Response to exercise after blood loss and reinfusion. J Appl
- 318 Physiol 1972;33(2):175-80.
- 319 6. Lasne F, Martin L, Crepin N, et al. Detection of isoelectric profiles of erythropoietin in urine:
- 320 differentiation of natural and administered recombinant hormones. *Anal Biochem* 2002;311(2):119-26.
- 321 doi: S0003269702004074 [pii] [published Online First: 2002/12/10]
- 322 7. Ashenden M, Morkeberg J. Net haemoglobin increase from reinfusion of refrigerated vs. frozen red
- blood cells after autologous blood transfusions. Vox Sang 2011;101(4):320-6. doi: 10.1111/j.1423-
- 324 0410.2011.01493.x [published Online First: 2011/05/04]


- 325 8. Boning D, Maassen N, Pries A. The Hematocrit Paradox How Does Blood Doping Really Work?
- 326 Int J Sports Med 2011;32(4):242-46. doi: 10.1055/s-0030-1255063
- 9. Schmidt W, Prommer N. Impact of alterations in total hemoglobin mass on VO 2max. Exerc Sport
- 328 *Sci Rev* 2010;38(2):68-75. doi: 10.1097/JES.0b013e3181d4957a [published Online First: 2010/03/26]
- 329 10. Lundby C, Montero D, Joyner M. Biology of VO2 max: looking under the physiology lamp. Acta
- 330 *Physiol (Oxf)* 2017;220(2):218-28. doi: 10.1111/apha.12827 [published Online First: 2016/11/27]
- 331 11. Valeri CR, Ragno G, Pivacek LE, et al. An experiment with glycerol-frozen red blood cells stored
- 332 at -80 degrees C for up to 37 years. Vox Sang 2000;79(3):168-74. doi: 10.1159/000031236 [published
- 333 Online First: 2000/12/09]
- 334 12. MacLare G. Request for the extended storage of frozen red cells beyond 10 years to be considered
- for inclusion within UK Guidelines. 2016
- 336 13. Bizjak DA, Jungen P, Bloch W, et al. Cryopreservation of red blood cells: Effect on rheologic
- properties and associated metabolic and nitric oxide related parameters. Cryobiology 2018;84:59-68.
- doi: 10.1016/j.cryobiol.2018.08.001 [published Online First: 2018/08/07]
- 339 14. Pallotta V, D'Amici GM, D'Alessandro A, et al. Red blood cell processing for cryopreservation:
- 340 from fresh blood to deglycerolization. Blood Cells Mol Dis 2012;48(4):226-32. doi:
- 341 10.1016/j.bcmd.2012.02.004 [published Online First: 2012/03/20]
- 342 15. Walpurgis K, Kohler M, Thomas A, et al. Storage-induced changes of the cytosolic red blood cell
- 343 proteome analyzed by 2D DIGE and high-resolution/high-accuracy MS. Proteomics
- 344 2012;12(21):3263-72. doi: 10.1002/pmic.201200280
- 345 16. Holovati JL, Wong KA, Webster JM, et al. The effects of cryopreservation on red blood cell
- 346 microvesiculation, phosphatidylserine externalization, and CD47 expression. Transfusion (Paris)
- 347 2008;48(8):1658-68. doi: 10.1111/j.1537-2995.2008.01735.x [published Online First: 2008/05/17]
- 348 17. Hult A, Malm C, Oldenborg PA. Transfusion of cryopreserved human red blood cells into healthy
- 349 humans is associated with rapid extravascular hemolysis without a proinflammatory cytokine
- 350 response. Transfusion (Paris) 2013;53(1):28-33. doi: 10.1111/j.1537-2995.2012.03710.x
- 351 18. Hult A, Fredrik T, Christer M, et al. Phagocytosis of liquid-stored red blood cells in vitro requires
- 352 serum and macrophage scavenger receptors. Submitted 2015
- 353 19. Mock DM, Matthews NI, Zhu S, et al. Red blood cell (RBC) survival determined in humans using
- 354 RBCs labeled at multiple biotin densities. Transfusion (Paris) 2011;51(5):1047-57. doi:
- 355 10.1111/j.1537-2995.2010.02926.x

- 356 20. D'Alessandro A, Gray AD, Szczepiorkowski ZM, et al. Red blood cell metabolic responses to
- 357 refrigerated storage, rejuvenation, and frozen storage. Transfusion (Paris) 2017;57(4):1019-30. doi:
- 358 10.1111/trf.14034 [published Online First: 2017/03/16]
- 359 21. Poisson JS, Acker JP, Briard JG, et al. Modulating Intracellular Ice Growth with Cell-Permeating
- 360 Small-Molecule Ice Recrystallization Inhibitors. Langmuir 2019;35(23):7452-58. doi:
- 361 10.1021/acs.langmuir.8b02126 [published Online First: 2018/08/19]
- 362 22. Berglund B, Ekblom B, Ekblom E, et al. The Swedish Blood Pass project. Scand J Med Sci Sports
- 363 2007;17(3):292-7.
- 23. Pialoux V, Mounier R, Brugniaux JV. Hemoglobin and hematocrit are not such good candidates to
- detect autologous blood doping. Int J Hematol 2009;89(5):714-5. doi: 10.1007/s12185-009-0330-5
- 366 [published Online First: 2009/05/21]
- 367 24. Thevis M, Kohler M, Schanzer W. New drugs and methods of doping and manipulation. Drug
- 368 discovery today 2008;13(1-2):59-66. doi: \$1359-6446(07)00492-8 [pii]
- 369 10.1016/j.drudis.2007.11.003 [published Online First: 2008/01/15]
- 370 25. Morkeberg JS, Belhage B, Damsgaard R. Changes in blood values in elite cyclist. Int J Sports Med
- 371 2009;30(2):130-8. doi: 10.1055/s-2008-1038842 [published Online First: 2008/09/06]
- 372 26. Bejder J, Hoffmann MF, Ashenden M, et al. Acute hyperhydration reduces athlete biological
- passport OFF-hr score. Scand J Med Sci Sports 2015 doi: 10.1111/sms.12438
- 27. Pottgiesser T, Schumacher YO, Funke H, et al. Gene expression in the detection of autologous
- blood transfusion in sports--a pilot study. Vox Sang 2009;96(4):333-6. doi: VOX1169 [pii]
- 376 10.1111/j.1423-0410.2009.01169.x [published Online First: 2009/03/04]
- 377 28. Gore CJ, Parisotto R, Ashenden MJ, et al. Second-generation blood tests to detect erythropoietin
- abuse by athletes. Haematologica 2003;88(3):333-44. [published Online First: 2003/03/26]
- 379 29. Monfort N, Ventura R, Latorre A, et al. Urinary di-(2-ethylhexyl)phthalate metabolites in athletes
- 380 as screening measure for illicit blood doping: a comparison study with patients receiving blood
- 381 transfusion. *Transfusion (Paris)* 2009;50(1):145-9. doi: TRF2352 [pii]
- 382 10.1111/j.1537-2995.2009.02352.x [published Online First: 2009/08/22]
- 383 30. Pottgiesser T, Umhau M, Ahlgrim C, et al. Hb mass measurement suitable to screen for illicit
- 384 autologous blood transfusions. Med Sci Sports Exerc 2007;39(10):1748-56. doi:
- 385 10.1249/mss.0b013e318123e8a6

- 386 00005768-200710000-00011 [pii] [published Online First: 2007/10/03]
- 31. Morkeberg J, Sharpe K, Belhage B, et al. Detecting autologous blood transfusions: a comparison
- of three passport approaches and four blood markers. Scand J Med Sci Sports 2011;21(2):235-43. doi:
- 389 10.1111/j.1600-0838.2009.01033.x [published Online First: 2009/11/12]
- 390 32. Thevis M, Kuuranne T, Walpurgis K, et al. Annual banned-substance review: analytical
- 391 approaches in human sports drug testing. Drug Test Anal 2016;8(1):7-29. doi: 10.1002/dta.1928
- 392 33. Fitch KD. Blood doping at the Olympic Games. J Sport Med Phys Fit 2017;57(11):1526-32. doi:
- 393 10.23736/S0022-4707.17.06948-1
- 394 34. Al-Thani AM, Voss SC, Al-Menhali AS, et al. Whole Blood Storage in CPDA1 Blood Bags Alters
- 395 Erythrocyte Membrane Proteome. Oxid Med Cell Longev 2018;2018:6375379. doi:
- 396 10.1155/2018/6375379 [published Online First: 2018/12/12]
- 35. Bylesjo M, Eriksson D, Sjodin A, et al. Orthogonal projections to latent structures as a strategy for
- 398 microarray data normalization. BMC Bioinformatics 2007;8:207. doi: 1471-2105-8-207 [pii]
- 399 10.1186/1471-2105-8-207 [published Online First: 2007/06/20]
- 400 36. Pohjanen E, Thysell E, Jonsson P, et al. A multivariate screening strategy for investigating
- 401 metabolic effects of strenuous physical exercise in human serum. J Proteome Res 2007;6(6):2113-20.
- 402 doi: 10.1021/pr070007g [published Online First: 2007/04/13]
- 403 37. Wold S, Esbensen K, Geladi P. Principal Component Analysis. Chemometrics and Intelligent
- 404 *Laboratory Systems* 1987;2:37-52.
- 405 38. Trygg J, Holmes E, Lundstedt T. Chemometrics in metabonomics. J Proteome Res 2007;6(2):469-
- 406 79. doi: 10.1021/pr060594q [published Online First: 2007/02/03]
- 407 39. Aikin R, Baume N, Equey T, et al. Biomarkers of doping: uses, discovery and validation.
- 408 Bioanalysis 2020 doi: 10.4155/bio-2020-0035 [published Online First: 2020/06/02]
- 409 40. Brun V, Couté Y, editors. Proteomics for Biomarker Discovery: Methods and Protocols.
- 410 Université Grenoble Alpes, CEA, Inserm, BGE U1038GrenobleFrance: Human Press, 2019.
- 41. Bosman GJ. Survival of red blood cells after transfusion: processes and consequences. Front
- 412 *Physiol* 2013;4:376. doi: 10.3389/fphys.2013.00376
- 413 42. Hult A. Towards a detailed understanding of the red blood cell storage lesion: and its
- consequences for in vivo survival following transfusion. Umeå Universiy, 2015.

- 43. Schmidt W, Prommer N. The optimised CO-rebreathing method: a new tool to determine total
- 416 haemoglobin mass routinely. Eur J Appl Physiol 2005;95(5-6):486-95. doi: 10.1007/s00421-005-
- 417 0050-3 [published Online First: 2005/10/14]
- 41. 44. Siebenmann C, Keiser S, Robach P, et al. CORP: The assessment of total hemoglobin mass by
- 419 carbon monoxide rebreathing. J Appl Physiol 2017;123(3):645-54. doi:
- 420 10.1152/japplphysiol.00185.2017 [published Online First: 2017/07/01]
- 421 45. Celsing F, Nystrom J, Pihlstedt P, et al. Effect of long-term anemia and retransfusion on central
- 422 circulation during exercise. *J Appl Physiol* (1985) 1986;61(4):1358-62.
- 423 46. Karsten E, Breen E, Herbert BR. Red blood cells are dynamic reservoirs of cytokines. Sci Rep
- 424 2018;8(1):3101. doi: 10.1038/s41598-018-21387-w
- 425 47. Carvalho AS, Rodriguez MS, Matthiesen R. Red Blood Cells in Clinical Proteomics. *Methods Mol*
- 426 *Biol* 2017;1619:173-81. doi: 10.1007/978-1-4939-7057-5_13
- 427 48. Malcovati L, Pascutto C, Cazzola M. Hematologic passport for athletes competing in endurance
- 428 sports: a feasibility study. *Haematologica* 2003;88(5):570-81.
- 429 49. Pottgiesser T, Echteler T, Sottas PE, et al. Hemoglobin mass and biological passport for the
- 430 detection of autologous blood doping. Med Sci Sports Exerc 2012;44(5):835-43. doi:
- 431 10.1249/MSS.0b013e31823bcfb6

- 432 50. Sallet P, Brunet-Guedj E, Mornex R, et al. Study of a new indirect method based on absolute
- 433 norms of variation to detect autologous blood transfusion. Int J Hematol 2008;88(4):362-8. doi:
- 434 10.1007/s12185-008-0182-4 [published Online First: 2008/10/24]



Erythrocytes (cells 10¹²·L⁻¹)

